A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis
Published in
American Journal of Obstetrics & Gynecology, March 2018
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2024.
All research outputs
#2,700,974
of 34,560,275 outputs
Outputs from American Journal of Obstetrics & Gynecology
#2,783
of 17,658 outputs
Outputs of similar age
#43,307
of 378,888 outputs
Outputs of similar age from American Journal of Obstetrics & Gynecology
#53
of 101 outputs
Altmetric has tracked 34,560,275 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,658 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,888 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
